New drug duo targets genetic driver in Tough-to-Treat blood cancer
NCT ID NCT06876142
Summary
This study is testing a combination of two oral drugs, mirdametinib and sirolimus, for people with advanced multiple myeloma that has returned or stopped responding to many other treatments and has specific genetic changes (KRAS or NRAS mutations). The goal is to find a safe dose and see if blocking two cancer growth pathways can help control the disease. Participants take both drugs daily at home for up to one year, followed by long-term monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.